Selective serotonin reuptake inhibitors in affective disorders - II. Efficacy and quality of life

Journal of Psychopharmacology

Volumn 12, Issue 3 SUPPL. B, 1998, Pages

  Goodnick, Paul J ^a   Goldstein, Burton J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Acute; Cognitive dysfunction; Continuation; Melancholic; Psychomotor agitation; Quality of life; Sleep disturbance

Indexed keywords

CITALOPRAM; FLUOXETINE; MIANSERIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

AFFECTIVE NEUROSIS; AGED; ANXIETY NEUROSIS; CLINICAL TRIAL; DEPRESSION; DRUG DOSE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MELANCHOLIA; META ANALYSIS; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QUALITY OF LIFE; RESTLESSNESS; REVIEW; SLEEP DISORDER;

EID: 0031792537     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269881198012003031     Document Type: Review

References (205)

1. Aguglia E, Casacchia M, Cassano GB, Faravelli C, Ferrari G, Giordano P, Pancheri P, Ravizza L, Trabucchi M, Bolino F, Scarpato A, Berardi D, Provenzano G, Brugnoli R, Rozzini R (1993) Double-blind study of the efficacy and safety of sertraline vs fkioxetine in major depression. Int Clin Psychopharmaeol 8: 197-202.
2. Alderman J, Wolkow R, Chung M, Johnston H (1998) Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: Pharmacokinetics, tolerability and efficacy. J Am Acad Child Adolesc Psychiatry 37: 386-394.
3. Altamura AC, Percudani M, Guercetti G, Invernizzi G (1989) Efficacy and tolerability of fluoxetine in the elderly: a double-blind study versus amitriptyline. Int Clin Psychopharmacol 4: 103-106.
4. American Psychiatric Association (1993) Practice guidelines for major depressive disorder in adults. Am J Psychiatry 150: 1-23.
5. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edition. American Psychiatric Press, Washington.
6. Amsterdam J (1998) Efficacy of selective serotonin reuptake inhibitors in melancholic depression. J Psychopharmacol 12(3) (Suppl. B): S99-S111.
7. Angst J. Scheidegger P, Stabl, M (1993) Efficacy of moclobemide in different patient groups. Results of new subscales of the Hamilton Depression Rating Scale. Clin Neuropharmacol 16 (Suppl. 2): S55-S62.
8. Ansseau M, Gabriels A, Loyens J, et al. (1993) A double blind comparison of paroxetine and fluvoxamine in major depression. Eur Neuropsychopharmacol 3 (3): 323-324.
9. Ayd FJ (1991) Does a therapeutic window explain loss of therapeutic effect with fluoxetine? Int Drug Ther Newslett 26: 33-34.
10. Bauender JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP (1998) Double-blind, fixed dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155:36-42.
11. Beasley CM, Sayler M E, Bosomworth JC, Wernicke JF (1991) Highdose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychopharmacol 11:166-174.
12. Beasley CM Jr, Holman SR, Porvin JH (1993) Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 5: 199-207.
13. Behan P, Berti C, Doogan DP (1994) Sertraline and clomipramine in atypical depression-a double-blind study. Poster presented at XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress, Washington DC.
14. Bennett KJ, Torrance GW, Boyle MH, et al. (1996) Utility-based measures of health-related quality of life in depression. Eur Neuropsychopharmacol 6:128.
15. Bennie EH, Mullin JM, Martindale JJ (1995) A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 56: 229-237.
16. Berti C, Wilson K, Whitehead A (1997) Sertraline efficacy in elderly patients suffering from major depression. New Research Programs and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego
17. Bisserbe JC, Lane R, Wiseman R (1996a) Predictors of response to SSRIs in patients with major depression. Eur Neuropsychopharmacol 6 (Suppl. 3): 122.
18. Bisserbe JC, Lane RM, Flament M, Franco-Belgian OCD (1997) A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 12: 82-93.
19. Blehar MC, Lewy AJ (1990) Seasonal mood disorders. Psychopharm Bull 26: 465-494.
20. Bouchard RH, Pourcher E, Vincent P (1989) Fluoxetine and extrapyramidal side-effects. Am J Psychiatry 146: 1352-1353.
21. Bougerol T, Scotto JC, Patris M, Strib M, Lemming O, Petersen HEH (1997) Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice. Clin Drug Invest 14: 77-89.
22. Bowden CL, Schatzberg AF, Rosenbaum A, Contreras SA, Samson JA, Dessain E, Sayler M (1993) Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 13: 305-311.
23. Boyer P, Danion JM, Bisserbe J-C, Hotton JM, Troy S (1998) Clinical and economic comparison of sertraline and fluoxetine in depression: a 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 13: 157-169.
24. Brown AS, Gershon S (1993) Dopamine and depression. J Neural Transm Gen Sect 91: 75-109.
25. BurkeWJ, Hendricks SE, McArthur-Campbell D, Jacques D, Stull T (1996) Fluoxetine and norfluoxetine serum concentrations and clinical response in weekly versus daily dosing. Psychopharmacol Bull 32: 27-32.
26. Burke WJ, Dewan V, Wengel SP, Roccaforte WH, Nadolny GC, Folks DG (1997) The use of selective serotonin uptake inhibitors for depression and psychosis complicating dementia. Int J Ger Psychiatry 12: 519-525.
27. Burns BJ, Larsen DB, Goldstrom JD, Johnson WE, Taube C, Miller NE, Mathis ES (1988) Mental disorder among nursing home patients: preliminary findings from the national nursing home survey pretest. Int J Geriatr Psychiatry 3: 27-35.
28. Cain JW (1992) Poor response to fluoxetine: underlying depression, serotonergic overstimulation or a 'therapeutic window'? J Clin Psychiatry 53: 272-277.
29. Clayton P, Grove WM, Coryell W, Keller M, Hirschfield R, Fawcett J (1991) Follow-up and family study of anxious depression. Am J Psychiatr 148 (Suppl. II): 1512-1517.
30. Clerc GE, Ruimy P, Verdeau-Pailles J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatients Study Group. Int Clin Psychopharmacol 9: 139-143.
31. Cohn CK, Shrivastava R, Mendels J, Cohn JB, Fahre LF, Claghorn JL, Dessain EC, Itil TM, Lautin A (1990) Double-blind multicenter comparison of sertraline and amitriptyline in elderly depressed patients J Clin Psychiatry 51 (Suppl. B): 28-33.
32. Daamen MJ, Brown WA (1992) Single-dose fluoxetine in management of premenstrual syndrome [letter]. J Clin Psychiatry 53: 210-211.
33. Danish University Antidepressant Group (1986) Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology 90: 131-138.
34. Danish University Antidepressant Group (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 18: 289-299.
35. Davis R, Wilde MI (1996) Sertraline: a pharmacoeconomic evaluation of its use in depression. Pharmacoeconomics 10: 409-131.
36. De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S (1993) A double-blind, comparative multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 87: 141-145.
37. de Jonghe F, Swinkels J (1997) Selective serotonin reuptake inhibitors. Relevance or differences in their pharmacological and clinical profiles. CNS Drugs 7: 452-467.
38. Diamond B, Hamner M, Sunde D (1989) Possible tolerance to the antidepressant, anti-obsessive-compulsive and analgesic effects of fluoxetine. Biol Psychiatry 25 (Suppl. 7A): 155.
39. Doogan DP, Caillard V (1992) Sertraline in the prevention of depression. Br J Psychiatry 160: 217-222.
40. Doogan DP, Langdon CJ (1994) A double-blind, placebocontrolled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 9: 95-100.
41. Dorsey CM, Lukas SE, Cunningham SL (1996) Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacology 14: 437-442.
42. Dunner DL, Dunbar GC (1992) Optimal dose regimen for paroxetine. J Clin Psychiatry 53 (Suppl. 2): 21-26.
43. Edwards RA, Newburn G (1994) Sertraline vs clomipramine in major depression: a single blind trial. Paper presented at 29th Congress of the Royal Australian and New Zealand College of Psychiatrists, Tasmania.
44. Ellingrod VL, Perry PJ (1994) Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 51: 3033-3046.
45. Eriksson E, Hedberg MA, Andersch B, Sunblad C (1995) The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12: 167-176.
46. European Union (1994) Guidelines for psychotropic drugs: antidepressant medicinal products. Eur Neuropsychopharmacol 4: 62-65.
47. Evans ME, Copeland JRM, Dewey ME (1991) Depression in the elderly in the community: effect of physical illness and selected social factors. J Geriatr Psychiatry 6: 787-795.
48. Fabre LF, Crismon L (1985) Efficacy of fluoxetine in outpatients with major depression. Curr Ther Res 37: 1.
49. Fava M, Rosenbaum JF, Cohen L, Reiter S, McCarthy M, Steingard R, Clancy K (1992) High dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord 25: 229-234.
50. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Dube S, Small JG (1995) Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry 38: 592-602.
51. Fava M, Rappe M, Pava AA, Nierenberg AA, Alpert JE, Rosenbaum JF (1995) Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 56: 52-55.
52. Fava M, Rush J, Shelton RC, Thase ME, Koran LM (1997) Treatment response in dysthymic patients with and without a history of MDD. New Research Programs and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego.
53. Feiger A, Kiev A, Shrivastava R, Wisselink PG, Wilcox CS (1996) Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57: 53-62.
54. Feighner JP, Boyer WF, Meredith CH, Hendrickson GG (1989) A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 4: 239-244.
55. Feighner J, Overo K, Fieve R, Carman J, Cunningham L, Schwartz G (1997) Fixed dose comparison of citaiopram versus placebo in the treatment of outpatients with moderate to severe depression. Paper presented at the 37th Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton.
56. Fichtner C G, Jobe TH, Braun BG (1991) Does fluoxetine have a therapeutic window? Lancet 338: 520-521.
57. Finkel SI (1996) Antidepressant therapy in the old-old. J Clin Psychiatry 57 (Suppl. 5): 23-28.
58. Finkel SI, Richter EM (1995) Double-blind comparison of sertraline and nortriptyline in late-life depression. Eur Neuropsychopharmacol 5: 314.
59. Fournier J-P, Lane RM, Chouinard G,Watson DB, Amin M, Remick RA, Thorpe LU (1997) The efficacy and safety of sertraline us. imipramine in outpatients with major depression: a six-month, parallel, double-blind, multicenter study. Hum Psychopharmacol 12: 203-215.
60. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM (1991) Conceptualization and rationale for the consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psy 48: 851-855.
61. Freeman EW, Rickels K, Sondheimer SJ, Wittmaack FM (1996) Sertraline versus desipramine in the treatment of premenstrual syndrome: an open-label trial. J Clin Psychiatry 57: 7-11.
62. Friedhoff A, Alpert M, Clary C, Richter E (1998) Sertraline versus nortriptyline in the depressed elderly with and without melancholia: effects on anxiety, depression, sleep and energy. Poster presented at the American Association of Geriatric Psychiatry, San Diego.
63. Gagiano C A (1993) A double-blind study to compare paroxetine and fluoxetine in patients with major depression. Br J Clin Res 4:145-152.
64. Gattaz WF, Bogel P, Kick H, Kohnen R (1995) Moclobemide versus fluoxetine in the treatment of inpatients with major depression. J Clin Psychopharmacol 15 (Suppl. 2): 35S-40S.
65. Geretsegger C, Bohmer F, Ludwig M (1994) Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects. Int Clin Psychopharmacol 9: 25-29.
66. Giardino L, Zanni M, Bettelli C, Savina MA, Calza L (1996) Regulation of glutamic acid decarboxylase mRNA expression in rat brain after sertraline treatment. Eur J Pharmacol 312: 183-187.
67. Goldberg JF, Sacks MH, Kocsis JH (1995) Attenuation of response to serotonin reuptake inhibitors [letter]. Am J Psychiatry 152: 954.
68. Goldstein B, Goodnick P (1998) Selective serotonin reuptake inhibitors in affective disorders. III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12(3) (Suppl. B): S55-S87.
69. Goodnick RJ, Extein IL (1989) Buproprion and fluoxetine in depressive subtypes. Ann Clin Psychiatry 1: 119-122.
70. Gram LF (1994) Fluoxetine. New Engl J Med 331: 1354-1361.
71. Greden JF (1993) Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry 54 (Suppl. 8): 39-47.
72. Gregor KJ, Riley JA, Downing DK (1996) Concomitant use of anxiolytics and hypnotics with selective serotonin reuptake inhibitors. Clin Ther 18: 521-527.
73. Griest J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C (1995) Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52: 289-295.
74. Halbreich U, Smoller JW (1997) Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. J Clin Psychiatry 58: 399-402.
75. Hegerl U, Gallinat J, Moeller H-J, Arato M, Janka Z (1997) Double-blind, multicenter comparative study of sertraline and amitriptyline in hospitalized patients with major depression. Eur Neuropsychopharmacol 7 (Suppl. 2): S180.
76. Heiligenstein JH, Tollefson GD, Faries DE (1993) A double-blind trial of fluoxetine, 20mg, and placebo in out-patients with DSM-III-R major depression and melancholia. Int Clin Psychopharmacol 8: 247-251.
77. Heiligenstein JH, Ware JE Jr, Beusterien KM. Roback PJ, Andrejasich C, Tollefson GD (1995) Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression. Int Psychoger 7 (Suppl.): 125-137.
78. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, Burrows K, Poster M, Cantillon M, Winston A (1993) A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry 150: 1169-1175.
79. Hendrickse WA, Roffwarg HP, Grannemann BD, Orsulak PJ, Armitage R, et al. (1994) The effects of fluoxetine on the polysomnogram of depressed outpatients: a pilot study. Neuropsychopharmacology 10: 85-91.
80. Hylan TR, Neslusan CA, Baldridge RM, Meneades L, Crown WH, et al. (1997) SSRI antidepressant selection and anxiolytic and sedative-hypnotic use. J Clin Outcomes Management 4: 16-22.
81. Jacobs BL, Azmitia EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72: 165-229.
82. Joffe RT, Levitt AJ, Sokolov STH (1996) Augmentation strategies: focus on anxiolytics. J Clin Psychiatry 57 (Suppl. 7): 25-31.
83. Kelly MW, Perry PJ, Holstad SG, Garvey MJ (1989) Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 11: 165-170.
84. Kiev A, Feiger A (1997) A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 58: 146-152.
85. Kocsis JH, Schatzberg AF, Rush AJ, Korstein S, Klein D, Hirshfield RMA (1997) Maintenance therapy of chronic depression: a placebo-controlled trial of sertraline. Biol Psychiatry 42: 240S.
86. Koran LM, Friedman R, Kornstein SK, DeBattista C, Howland RH (1997) Sertraline versus imipramine in treating chronic depression: continuation treatment. New Research abstracts. Paper presented at the 150th Annual Meeting American Psychiatric Association, San Diego.
87. Lam RW, German CP, Michalon M, Steiner M, Levitt A, Corral MR, Watson GD, Morehouse RL, Tam W, Joffe RT (1995) Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry 152: 1765-1770.
88. Lane RM (1998) SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment 1998. J Psychopharmacol 12: 208-230.
89. Lane R, Baldwin D (1997) Selective serotonin reuptake inhibitorinduced serotonin syndrome. J Clin Psychopharmacol 17: 208-221.
90. Lane R, Fischler B (1995) The serotonin syndrome: coadministration, discontinuation and washout periods for the selective serotonin reuptake inhibitors (SSRIs). J Serotonin Res 3: 171-180.
91. Lane R, McDonald G (1994) Reducing the economic burden of depression. Int Clin Psychopharmacol 9: 229-243
92. Lapierre YD (1991) Controlling acute episodes of depression. Int Clin Psychopharmacol 6: 23-35.
93. Latimer PR, Ravindran AV, Bernatchez J-P, et al. (1996) Sertraline versus fluoxetine in the treatment of major depression. Poster presented at the World Congress of Psychiatry, Madrid.
94. Lauritzen L, Odgaard K, Clemmesen L, Lunde M, Öhrstrom J, Black C, Bech P (1996) Relapse prevention by means of paroxetine in ECT-treated patients with major depression: a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatrica Scand 94: 241-251.
95. Leinonen E, Koponen H, Lepola U (1993). Delirium during fiuoxetine treatment. A case report. Ann Clin Psychiatry 5: 255-257
96. Lepine J, Wiseman R (1996) Treatment of severe major depression: a double-blind study of sertraline and clomipramine. Eur Neuropsychopharmacol 6: 123.
97. Lepine JP, Wiseman RL, Zhu G (1997) A double-blind efficacy and safety study of sertraline and clomipramine in severe major depression. Biol Psychiatry 42: 249S.
98. Lipinski JF, Mallya G, Zimmerman P, Pope HG (1989) Fluoxetine induced akathisia: clinical and theoretical implications. J Clin Psychiatry 50: 39-42.
99. Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, Rosenthal M, Weise C (1998) Sertraline in the treatment of panic disorder: a multisite, double-blind, placebocontrolled fixed dose investigation. Br J Psychiatry 173: 54-60.
100. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O (1994) Moclobemide and fluoxetrne in atypical depression: a double blind trial. J Affect Disord 32: 169-177.
101. Mackay F, Dunn N, Wilton L, Pearce GL, Freemantle SN, Mann RD (1997) A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Safety 6: 235-246.
102. Malt UF (1995) Practical aspects of long-term treatment. Eur Neuropsychopharmacol 5: 288-289.
103. McEntee WJ, Mair RG, Langlais PJ (1987) Neurochemical specificity of learning: dopamine and motor learning. Yale J Biol Med 60: 187-193.
104. McEntee W, Ko G, Richter E (1996) Sertraline and nortriptyline: heart rate, cognitive improvement and quality of life in the depressed elderly. Eur Neuropsychopharmacol 6 (Suppl. 3): 36.
105. McGrath PJ, Quitkin FM, Klein DF (1995) Bromocriptine treatment of relapses seen during selective serotonin re-uptake inhibitor treatment of depression. J Clin Psychopharmacol 15: 289-291.
106. Mendels J (1992) The acute and long-term treatment of major depression. Int Clin Psychopharmacol 7: 21-29.
107. Menkes DB, Taghavi E, Mason PA, Howard RC (1993) Fluoxetine's spectrum of action in premenstrual syndrome. Int Clin Psychopharmacol 8: 95-102.
108. Mesters P, Cosyns P, Dejaiffe G, Fanielle J, Gilles C, Godderis J, Gregoire J, de Leval N, Meire P, Mesotten F, et al. (1993) Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20mg, in ambulatory patients aged over 60 years. Int Clin Psychopharmacol 8: 337-340.
109. Michelson D, Reimherr FW, Beasley CM, Wilson M (1997) Optimal length of continuation therapy: a prospective assessment during fluoxetine long term treatment of MDD. New Reseach Program and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego.
110. Modigh K, Westberg P, Eriksson E (1992) Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopliarmacol 12: 251-261.
111. Moeller H-J, Goebel C, Glaser K (1997) Double-blind, muticenter comparative study of sertraline versus amitriptyline in outpatients with major depression. Eur Neuropsychopharmacol 7 (Suppl. 2): 179-180.
112. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, Moron P, Parant-Lucena N, Singer L, Danion JM, et al. (1988) The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 153: 69-76.
113. Montgomery SA, Fineberg N (1989) Is there a relationship between serotonin receptor subtypes and selectivity of response in specific psychiatric illness? Br J Psychiatry 155 (Suppl. 8): 63-70.
114. Montgomery SA, Green M, Baldwin D, Montgomery D (1989) Prophylactic treatment of depression; a public health issue. Neuropsychobiology 22: 214-219.
115. Montgomery SA, Baldwin D, Shah A, Green M, Fineberg N, Montgomery D (1990) Plasma-level response relationship with fluoxetine and zimelidine. Clin Neuropharmacol 13: S71-S75.
116. Montgomery SA, Doogan DP, Burnside R (1991) The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. Int Clin Psychopharmacol 6: 37-46.
117. Montgomery SA, Rasmussen JGC, Lyby K, Connor P, Tanghoj P (1992) Doseresponse relationship of citalopram 20mg, citalopram 40mg, and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 6 (Suppl. 5): 65-70.
118. Montgomery SA, Dunbar G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8: 189-195.
119. Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitter IW, Zohar J, Birkett M, Wood AJ, and The Lilly European OCD Study Group (1993) A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 3:143-152.
120. Montgomery S (1995) Serotonin, sertraline and depression. 9 (Suppl. 2): 179.
121. Moon CAL, Jago W, Wood K, Doogan DP (1994) A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorders and associated anxiety in general practice J Psychopharmacol 8: 171-176.
122. Moscovitch A, Blashko C, Wiseman R, Goldberg M, Martindale J (1995) A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Poster presented at the 148th Annual Meeting of the American Psychiatric Association, Miami.
123. Nedergaard S, Bolam JP, Greenfield SA (1988) Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature 333: 174-177.
124. Nemeroff CB, Ninan PT, Ballenger JC, Lydiard RB, Feighner J, Patterson WM, Greist JH (1995) Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression 3: 163-169.
125. Newhouse PA, Finkel SI, Richter EM (1995) SSRIs in the treatment of depressed out-patients aged 70 years and older. Eur Neuropsychopharmacol 5: 314.
126. Newhouse PA, Ko G, Richter EM (1996) Comparison of sertraline and fluoxetine in depressed geriatric outpatients: plasma levels and efficacy. Eur Neuropsychopharmacol 6 (Suppl. 3): 35.
127. Nierenberg AA (1994) The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 55 (Suppl. A): 55-59.
128. Nutt DJ (1995) The anxiety factor in depression. J Psychopharmacol 3 (Suppl. 2): 185-190.
129. Olie JP, Gunn KP, Katz E (1997) A double-blind placebo-controlled multicentre study of sertraline on the acute and continuation treatment of major depression. Eur Psychiatry 12: 34-41.
130. Ontiveros A, Garcia-Barriga C (1997) A double-blind comparative study of paroxetine and fluoxetine in outpatients with depression. Br J Clin Res 8: 23-32.
131. Oswald I, Adams K (1986) Effects of paroxetine on human sleep. Br J Clin Pharmacol 22: 97-99.
132. Ownby R, Goodnick PJ (1996) Monoamine-oxidase inhibitors. In Goodnick P J (ed), Predictors of treatment response in mood disorders. American Psychiatric Press, Washington, pp. 37-56.
133. Palmer BW, Boone KB, Lesser IM, Wohl MA, Berman N, Miller BL (1996) Neuropsychological deficits among older depressed patients with predominantly psychological or vegetative symptoms. J Affect Disord 41: 17-24.
134. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF (1996) Fluoxetine versus phenelzine in atypical depression. Biol Psychiatr 40: 1017-1020.
135. Parker G, Brotchie H (1992) Psychomotor change as a feature of depressive disorders: an historical overview. Aust N Z J Psychiatry 26: 146-155.
136. Patris M, Bouchard J-M, Bougerol T, Charbonnier J-F, Chevalier J-F, Clerc G, Cyran C, Van-Amerongen P, Lemming O, Hopfner Petersen HE (1996) Citalopram versus fluoxetine: a double-blind. controlled, multicentre, phase III trials in patients with unipolar depression treated in general practice. Int Clin Psyehopharmacol 11: 129-136.
137. Pearistein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA (1997) Comparison of fluoxetine, buproprion and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 17: 261-266.
138. Perlis ML, Giles DE, Buysse DJ, Tu X, Kupfer DJ (1997) Selfreported sleep disturbance as a prodromal symptom in recurrent depression. J Affect Disord 42: 209-212.
139. Peselow ED, Filippi A-M, Goodnick P, Barouche F, Fieve RR (1989) The short- and long-term efficacy of paroxetine HCl: B. Data from a double-blind cross-over study and from a year-long term trial vs. imipramine and placebo. Psychopharmacol Bull 25: 272-276.
140. Post RM, Susan R, Weiss SB (1992) Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiatry 25: 41-43.
141. Preskorn SH (1993) Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 94: 2-12.
142. Preskorn SH, Harvey AT (1996) Biochemical and clinical doseresponse curves with sertraline. Clin Pharmacol Ther 59:180.
143. Preskorn SH, Lane RM (1995) Sertraline 50mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 10: 129-141.
144. Preskorn S, Shad M, Alderman J, Lane R (1998) Fluoxetine: age and dose dependent pharmacokinetics and CYP 2C19 inhibition [abstract]. Clin Pharmacol Therap 63: 166
145. Rapport DJ, Calabrese JR (1993) Tolerance to fluoxetine [letter]. J Clin Psychopharmacol 13: 361.
146. Rascati K (1995) Drug utilization review of concomitant use of specific serotonin reuptake inhibitors or clomipramine with antianxiety/sleep medications. Clin Therapeutics 17: 786-790.
147. Raskind MA (1992) Depression in the elderly. Can J Psychiatry 37: 46-
148. Ravindran AV, Telner J, Bialik R, Charbonneau Y, Ellis J, Wiens A, Griffiths J, Zaharia M, Waddell C, Merali Z, Anisman H, Lapierre YD (1997) The combined efficacy of cognitive therapy and pharmacotherapy in primary dysthymia. Biol Psychiatry 42: 255S.
149. Ravindran A, Wiseman R (1997) A double-blind, placebo-controlled study of sertraline in the treatment of outpatients with dysthymia. New Research Programs and Abstracts. Paper presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego.
150. Reimherr FW, Wood DR, Byerley W, Brainard J, Grosser BI (1984) Characteristics of responders to fluoxetine. Psychopharmacol Bull 20: 70-72.
151. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil T, LaPierre YD, Masco HL, Mendels MD (1990) Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison in outpatients with major depression. J Clin Psychiatry 51 (Suppl. 12B): 18-27.
152. Reimherr FW, Cohn CK, Cole JO, Itil TM, LaPierre YD, Masco HL, Mendels J (1991) Antidepressant effects of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. Biol Psychiatry 29: 352S.
153. Rifkin A (1997) SSRI optimal dose remains at issue. J Clin Psychiatry 58: 87-88
154. Robert P, Montgomery SA (1995) Citalopram in doses of 2060mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 10 (Suppl. 1): 29-35.
155. Rodin J, McAvay G, Timko C (1988) A longitudinal study of depressed mood and sleep disturbances in elderly adults. J Gerontol 43: 45-53.
156. Roose SP, Glassman AH, Attia E, Woodring S (1994) Comparative efficacy of selective serotonin reuptake inhibitors in the treatment of melancholia. Am J Psychiatry 151: 1735-1739.
157. Russell J M, McCullough JP, Trapp G, et al. (1995) Response to antidepressant treatment in chronically depressed patients with comorbid personality disorder. Psychopharmacol Bull 31: 612.
158. Russell JM, Berndt E, Miceli R. Course and cost of treatment with SSRIs (1998) New Research Abstracts. American Psychiatric Association Annual Meeting, Toronto.
159. Saletu B, Frey R, Krupka M, et al. (1992) Sleep laboratory studies on the single-dose effects of serotonin reuptake inhibitors paroxetine and fluoxetine on human sleep and awakening qualities. Sleep 15: 226-235.
160. Schatzberg AP (1991) Dosing strategies for antidepressant agents. J Clin Psychiatry 52: 14-20.
161. Sclar DA, Robison LM, Skaer TL, Galin RS, Legg RF, Nemec NL, Hughes TE, Buesching DP, Morgan M (1995) Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. J Int Med Res 23: 395-412.
162. Sechter D, Lane RM (1997) Continuation therapy with selective serotonin reuptake inhibitors. J Serotonin Res 4: 65-111.
163. Sechter D, Troy S (1997) Double blind randomized comparative study of sertraline and fluoxetine in depressive outpatients. Biol Psychiatry 42: 259S.
164. Sharpley AL, Williamson DJ, Attenburrow MEJ, et al. (1996) The effects of paroxetine and nefazodone on sleep: a placebocontrolled trial. Psychopharmaeology 126: 50-54.
165. Shone W, Ludwig M (1993) A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 3: 34S-39S.
166. Simmons RG, Abress L, Anderson CR (1988) Quality of life after kidney transplantation: a prospective, randomized comparison of cyclosporine and conventional immuno-suppressive therapy. Transplantation 45: 415-421.
167. Small GW, Hamilton SH, Bystritsky A, Meyers BS, Nemeroff CB, and the Fluoxetine Collaborative Study Group (1995) Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Int Psychogeriatrics 7 (Suppl.): 41-53.
168. Sobin C, Sachkeim HA (1997) Psychomotor symptoms of depression. Am J Psychiatry 154: 4-17.
169. Segaard JA, Verbruggen WP, Goodwin DP (1997) A double-blind efficacy and tolerability study of sertraline and moclobemide in atypical depression. Biol Psychiatry 42: 248S-249S.
170. Stark P, Hardison CD (1985) A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in outpatients with major depression disorder. J Clin Psychiatry 46: 53-58.
171. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover D, Streiner D (1995) Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. New Engl J Med 332: 1529-1534.
172. Sternbach H (1991) The serotonin syndrome. Am J Psychiatry 148: 705-713.
173. Stewart JW, Rabkin JG, Quitkin FM, et al. (1993) Atypical depression. In Dunner DL (ed), Current psychiatric therapy. WB Saunders Company, Philadelphia, pp. 215-220.
174. Stratta P, Bolino F, Cupillari M, et al. (1991) A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 6: 193-196.
175. Sussman M, Stahl S (1996) Update in the pharmacotherapy of depression. Am J Med 101 (Suppl. 6A): 26S-36S.
176. Tanda G, Frau R, Di Chiara G (1996) Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology 127: 83-87.
177. Thase ME, Rush AJ (1995) In Bloom SE, Kupfer DJ (eds), Psychopharmacology. The fourth generation of progress. Raven Press, New York, pp. 1081-1097.
178. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, Rosenbaum J, Harrison W (1996) A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry 53: 777-784.
179. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG (1997a) Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 58: 16-21.
180. Thase ME, Keller MB, Hirshfield RMA, Schatzberg A (1997b) Double-blind crossover antidepressant study: sertraline vs imipramine. Biol Psychiatr 41: 91S.
181. Thompson C (1992) Bridging the gap between psychiatric practice and primary care. Int Clin Psychopharmacol 7 (Suppl. 2): 31-36.
182. Thompson C, Lane R, Wiseman R (1994) Safety and efficacy of sertraline in elderly versus young depressed patients in primary care. Neuropsychopharmacology 10: 106S.
183. Tignol J (1993) A double-blind randomized multicenter comparison of paroxetine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 13 (Suppl. 2): 18S-22S.
184. Tollefson GD. Holman SL (1993) Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int Clin Psychopharmacol 8: 253-259.
185. Tollefson GD, Griest JH, Jefferson JW, Heiligenstein JH, Sayier ME, Tollefson SL, Koback K (1994) Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol 14: 385-391.
186. Tollefson GD, Rampey AH Jr, Potvin JH, Jenike MA, Rush AJ, Kominguez RA, Koran LM, Shear MK, Goodman W, Genduso LA (1994) A multicenter investigation of fixed dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51: 559-567.
187. Turner R (1994) Quality of life: experience with sertraline. Int Clin Psychopharmacol 9 (Suppl. 3): 27-31.
188. Tyrer SP, Marshall EF, Griffiths HW (1990) The relationship between response to fluoxetine plasma drug levels, imipramine binding to platelet membranes and whole blood 5-HT. Prog Neuropsychopharmacol Biol Psychiatry 14: 797-805.
189. Van Houdenhove B, Onghena P, Floris M, Janssen F, De Nayer AR, Boxus A, Iancu H (1997) An open study of sertraline in acute and continuation treatment of depressed out-patients. J Int Med Res 25: 340-353.
190. Van Moffaert M, Bartholome F, Cosyns P, De-Nayer AR, Mertens C (1995) A controlled comparison of sertraline and fluoxetine in acute and continuation therapy of major depression. Hum Psychopharmacol 10: 393-405.
191. Vanelle JM, Arrar-Levy D, Poirer MF, Bouhassira M, Blin P, Olie J P (1997) Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry 170: 345-350.
192. Volkow ND, Gur RC, Wang G-J, Fowler JS, Moberg PJ, Ding Y-S, Hitzemann R, Smith G, Logan J (1998) Association between decline in brain dopamine activity with age and cognitive and motor impaiment in healthy individuals. Am J Psychiatry 155: 344-349.
193. Walczak DD, Apter JT, Halikas JA, Borison RL, Carman JS, Post GL, Patrick R, Cohn JB, Cunningham LA, Rittberg B, Preskorn SH, Kang JS, Wilcox CS (1996) The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Ann Clin Psychiatry 8: 139-151.
194. Wells KB, Stewart A, Hays RD, Burnam A, Rogers W, Daniels M, Berry S, Greenfield S, Ware J (1989) The functioning and wellbeing of depressed patients. Results from the Medical Outcomes Study. JAMA 262: 914-919.
195. Wernicke JF, Dunlop SR, Dornseif BE, Zerbe RL (1987) Fixed-dose fluoxetine therapy for depression. Psychopharmacol Bull 23: 164-168.
196. Wernicke JF, Dunlop SR, Dornseif BE, Bosomworth JC, Humbert M (1988) Low-dose fluoxetine therapy for depression. Psychopharmacol Bull 24: 183-188.
197. WHO Mental Health Collaborating Centres (1989) Pharmacotherapy of depressive disorders. A consensus statement. J Affect Disord 17: 197-198.
198. WHO (1992) International classification of diseases, 10th edn. World Health Organization, Geneva.
199. Wilner KD, Everson G, Foulds GH, Hansen RA, Shrestra R, McKinley C, McClain CJ. (1996a) Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of hepatic impairment. Eur Neuropsychopharmacol 6 (Suppl 3): 40.
200. Wilner KD, Baris BA, Foulds GH, Anziano RJ, Berl T, Ziegler MG (1996b) Multiple dose pharmacokinetics of sertraline in subjects with varying degrees of renal impairment. Eur Neuropsychopharmacol 6 (Suppl 3): 41.
201. Wilson SJ, Bell C, Coupland NJ, Nutt DJ (1994) Long-term effects of SSRIs and TCAs on sleep. Eur Neuropsychopharmacol 4: 314.
202. Wilson K, Berti C, Whitehead A (1997) The efficacy of sertraline in elderly patients suffering from major depression. Biol Psychiatry 42: 242S.
203. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severine S, Stout A, Stone A, Harrison W, and the Sertraline Premenstrual Dysphoric Collaborative Study Group (1997) Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA 278: 983-988.
204. Young SA, Hurt PH, Benedek DM, Howard RS (1997) Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 59: 76-80.
205. Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E (1996) Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression. Am J Psychiatry 153: 1631-1633.